Journal: Frontiers in Oncology

Article Title: Spatially resolved transcriptomics revealed local invasion-related genes in colorectal cancer

doi: 10.3389/fonc.2023.1089090

Figure Lengend Snippet: Cell differentiation trajectories in CRC obtained by pseudotime analysis. (A–D) tSNE map shows the results of the dimensionality reduction and clustering analysis of S112 (A) , S115 (B) , S114 (C) , and 927 (D) (up). Results of pseudotime cell trajectory in S112 (A) , S115 (B) , S114 (C) , and S927 (D) (down). (E) Twelve genes were screened by invasive modules. (F) The relationship of STC1 expression level and cancer stage/progression-free survival in colon cancer (up) and rectal cancer (down) from TCGA database. (G) The relationship of CES1 expression level and cancer stage in colon cancer (up) and rectal cancer (down) from TCGA database. (H) Immunohistochemical staining showed the expression of AKR1B1(left panel), STC1(middle panel), and CD47(right panel) in Mucosa and cancer(up) and Invasive margin(down) (n=45). The scale bars on the lower right are 100 µm. *P < 0.05, **P < 0.01 and ***P < 0.001. NS, not significant difference.

Article Snippet: Antibodies used include STC1 (1:50; Proteintech, China), RPL5(1:800; Proteintech, China), AKR1B1(1:50; BOSTER, China), HLA-A(1:100; BOSTER, China) and CD47(1:400; BOSTER, China).

Techniques: Cell Differentiation, Expressing, Immunohistochemical staining, Staining

Journal: Cancers

Article Title: Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development

doi: 10.3390/cancers12113225

Figure Lengend Snippet: Drugs in the Pipeline Newly Diagnosed AML/MDS.

Article Snippet: Unfortunately, studies with other anti-CD47 antibodies (e.g., CC-90002, Celgene, Summit, NJ, USA), were terminated early.

Techniques: Mutagenesis, Biomarker Discovery, Sequencing, Transplantation Assay, Inhibition, Drug discovery, Activity Assay

Journal: Biomarker Research

Article Title: The landscape overview of CD47-based immunotherapy for hematological malignancies

doi: 10.1186/s40364-023-00456-x

Figure Lengend Snippet: Overall structures of CD47, SIRPα and CD47 complex. A Structure of the ectodomain of human CD47 (PDB#2VSC). B Interaction of CD47 with three major ligands (SIRPα, TSP-1 and integrin). The figure was created by Biorender.com. C Complete extracellular region of human SIRPα (PDB#2WNG). The structures were reconstructed using VMD software. Abbreviations: CD47, cluster of differentiation 47; IgSF, immunoglobulin superfamily; ITIM, immunoreceptor tyrosine-based inhibitory motif; SHPS-1/2, protein tyrosine phosphatase substrate-1/2; SIRPα, signal-regulatory protein α; TSP-1: thrombospondin-1

Article Snippet: MIL-95 , CM-312 , KeyMed Biosciences Co Ltd , CD47 antagonist , anti-CD47 monoclonal antibody , Lymphoma , Phase I , Phase I , NCT04651348 , CTR20201108.

Techniques: Software

Journal: Biomarker Research

Article Title: The landscape overview of CD47-based immunotherapy for hematological malignancies

doi: 10.1186/s40364-023-00456-x

Figure Lengend Snippet: Macrophages distinguish between “self” or “non-self” by binding to SIRPα transmembrane protein on macrophage to form the CD47/SIRPα signaling complex. A CD47 expressed on cancer cell membrane binds to SIRPɑ on macrophage cell membrane to activate the “Don’t eat me” signal and block macrophage phagocytosis of cancer cells. B Blocking CD47-SIRPɑ interaction between cancer cell and macrophage induces phagocytosis by macrophage. Abbreviation: CD47, cluster of differentiation 47; SIRPα, signal-regulatory protein α

Article Snippet: MIL-95 , CM-312 , KeyMed Biosciences Co Ltd , CD47 antagonist , anti-CD47 monoclonal antibody , Lymphoma , Phase I , Phase I , NCT04651348 , CTR20201108.

Techniques: Binding Assay, Membrane, Blocking Assay

Journal: Biomarker Research

Article Title: The landscape overview of CD47-based immunotherapy for hematological malignancies

doi: 10.1186/s40364-023-00456-x

Figure Lengend Snippet: Inhibiting CD47/SIRPα axis regulates the fate of cancer cells . Inhibiting the CD47/SIRPα axis can ( A ) directly enhance phagocytosis of macrophages to tumor cells; B transform tumor-associated macrophages into an antitumor state and increase the recruitment of macrophages in tumors; C promote phagocytosis by dendritic cells and antigen presentation to CD8 + T-cells; (D) destroy tumor cells by natural killer cell-mediated ADCC and CDC; E increase tumor cell death, inhibit tumor cell proliferation, and prevent tumor cell migration. Abbreviation: CD47, cluster of differentiation 47; SIRPα, signal-regulatory protein α; ACDD: antibody-dependent cellular cytotoxicity; CDC: complement-dependent cytotoxicity

Article Snippet: MIL-95 , CM-312 , KeyMed Biosciences Co Ltd , CD47 antagonist , anti-CD47 monoclonal antibody , Lymphoma , Phase I , Phase I , NCT04651348 , CTR20201108.

Techniques: Immunopeptidomics, Migration

Journal: Biomarker Research

Article Title: The landscape overview of CD47-based immunotherapy for hematological malignancies

doi: 10.1186/s40364-023-00456-x

Figure Lengend Snippet: CD47 antagonists currently entering clinical trials for treatment of lymphomas

Article Snippet: MIL-95 , CM-312 , KeyMed Biosciences Co Ltd , CD47 antagonist , anti-CD47 monoclonal antibody , Lymphoma , Phase I , Phase I , NCT04651348 , CTR20201108.

Techniques: Clinical Proteomics, Binding Assay

Journal: Biomarker Research

Article Title: The landscape overview of CD47-based immunotherapy for hematological malignancies

doi: 10.1186/s40364-023-00456-x

Figure Lengend Snippet: Published results of clinical trials on the use of CD47 antagonists in lymphomas

Article Snippet: MIL-95 , CM-312 , KeyMed Biosciences Co Ltd , CD47 antagonist , anti-CD47 monoclonal antibody , Lymphoma , Phase I , Phase I , NCT04651348 , CTR20201108.

Techniques: Clinical Proteomics, Drug discovery

Journal: Biomarker Research

Article Title: The landscape overview of CD47-based immunotherapy for hematological malignancies

doi: 10.1186/s40364-023-00456-x

Figure Lengend Snippet: CD47 antagonists currently entering clinical trials for treatment of hematological tumors

Article Snippet: MIL-95 , CM-312 , KeyMed Biosciences Co Ltd , CD47 antagonist , anti-CD47 monoclonal antibody , Lymphoma , Phase I , Phase I , NCT04651348 , CTR20201108.

Techniques: Clinical Proteomics, Binding Assay

Journal: Biomarker Research

Article Title: The landscape overview of CD47-based immunotherapy for hematological malignancies

doi: 10.1186/s40364-023-00456-x

Figure Lengend Snippet: Published results of clinical trials on the use of CD47 antagonists in hematological tumors

Article Snippet: MIL-95 , CM-312 , KeyMed Biosciences Co Ltd , CD47 antagonist , anti-CD47 monoclonal antibody , Lymphoma , Phase I , Phase I , NCT04651348 , CTR20201108.

Techniques: Clinical Proteomics, Drug discovery

Journal: Biomarker Research

Article Title: The landscape overview of CD47-based immunotherapy for hematological malignancies

doi: 10.1186/s40364-023-00456-x

Figure Lengend Snippet: Future strategies for developing CD47 antagonists . Abbreviation: CD47, cluster of differentiation 47; SIRP, signal-regulatory protein

Article Snippet: MIL-95 , CM-312 , KeyMed Biosciences Co Ltd , CD47 antagonist , anti-CD47 monoclonal antibody , Lymphoma , Phase I , Phase I , NCT04651348 , CTR20201108.

Techniques:

Journal: bioRxiv

Article Title: The Antitumor Activities of Anti-CD47 Antibodies Require Fc-FcγR interactions

doi: 10.1101/2023.06.29.547082

Figure Lengend Snippet: (A) Average growth ± SEM of sq. MC38 tumors in WT (right) or FcR-γ chain −/− mice (left), treated with Fc variants of anti-mCD47 ab (MIAP301) or control (50ug IT, d. 8,10,14 and 18). (B) Average of lung metastases ± (Min to Max) of WT mice inoculated IV with B16 tumor cells, treated with anti-mCD47 ab Fc variants (MIAP301) or control (20 mg/Kg IP, d. 1,4,7 and 11). (C) Average growth ± SEM of sq. B16 tumors in WT mice, treated with MIAP301 Fc variants or control (50ug IT, d. 8,10,14 and 18). (D) Average growth ± SEM of sq. B16 tumors in WT mice, treated with MIAP301 Fc variants or control (50 ug IT, d. 8,10,14 and 18) in combination with anti-gp75 ab (TA99-mIgG2a, 200 ug IP d. 8, 10, 14 and 18). (E) Average growth ± SEM of sq B16 tumors in WT mice, treated with MIAP301 Fc variants or control (50ug IT, d. 8,10,14 and 18) in combination with anti-PD-1 ab (RMP1–14-mIgG1-D265A, 200 ug IP d. 8, 10, 14 and 18).

Article Snippet: The variable heavy and light regions of the anti-CD47 antibodies MIAP301 (anti-mCD47 ab) and 2D3 (nonblocking anti-hCD47 antibody) were decoded by mass spectrometry analysis (Bioinformatics Solutions, Inc.).

Techniques: Control

Journal: bioRxiv

Article Title: The Antitumor Activities of Anti-CD47 Antibodies Require Fc-FcγR interactions

doi: 10.1101/2023.06.29.547082

Figure Lengend Snippet: (A) Established MC38 tumors were analyzed by flow cytometry 72 hours after treatment with Fc variants of anti-mCD47 ab (MIAP301). Quantification of intratumoral myeloid cell populations is shown. (B) Average growth ± SEM of sq. MC38 tumors pre-treated with clodronate- or control-liposomes (100 uL, d.4, 7), then treatment with MIAP301-mIgG2a or isotype control was given (50 ug IT, d. 8, 10, 14 and 18). (C) Average growth ± SEM of subcutaneous sq. MC38 tumors pre-treated with anti-CCR2 ab (MC-21) or isotype control (100 ug, d. 7), then treatment with MIAP301- mIgG2a or isotype control was given (50 ug IT, d. 8, 10, 14 and 18). (D) Bone marrow derived macrophages obtained from WT mice were cocultured with CFSE-labeled MC38 or B16 tumor cells in the presence of PBS (Control) or Fc-modified anti-mCD47 ab (MIAP301). Percentage of phagocytosis was determined by the percentage of CFSE + cells within the macrophage cell gate (CD11b + F480 + ). Analysis on fold changes compared to control is shown.

Article Snippet: The variable heavy and light regions of the anti-CD47 antibodies MIAP301 (anti-mCD47 ab) and 2D3 (nonblocking anti-hCD47 antibody) were decoded by mass spectrometry analysis (Bioinformatics Solutions, Inc.).

Techniques: Flow Cytometry, Control, Liposomes, Derivative Assay, Labeling, Modification

Journal: bioRxiv

Article Title: The Antitumor Activities of Anti-CD47 Antibodies Require Fc-FcγR interactions

doi: 10.1101/2023.06.29.547082

Figure Lengend Snippet: (A) Levels of expression of CD47 on T cell subsets isolated from MC38 tumors, quantification (left) and representative flow cytometry plots (right) are shown. (B) Percentage of CD4 + FOXP3 + T regs of total CD4 + T cells, and (C) Percentage of tetramer + (KSPWFTTL) cells of total CD8 + T cells from MC38 tumors 72 hours after treatment with Fc variants of anti-mCD47 abs (MIAP301). (D) Average growth ± SEM of sq. MC38 tumors pre-treated with anti-CD8 ab (2.43) or isotype control (100 ug. d.7, 12, 17), then treatment with MIAP301-mIgG2a or isotype control was given (50 ug IT, d. 8, 10, 14 and 18). (E, left) MC38 tumors were treated with MIAP301-mIg2a (50 ug every 3 days) until rejection was achieved. Then mice were rechallenged with MC38 cells (10 million, d. 90). (E, right) Average growth ± SEM of sq. MC38 tumors in mice that achieved rejection 90 days before (rechallenged grouped) or in and mice without prior implantation of MC38 tumors (naïve group).

Article Snippet: The variable heavy and light regions of the anti-CD47 antibodies MIAP301 (anti-mCD47 ab) and 2D3 (nonblocking anti-hCD47 antibody) were decoded by mass spectrometry analysis (Bioinformatics Solutions, Inc.).

Techniques: Expressing, Isolation, Flow Cytometry, Control

Journal: bioRxiv

Article Title: The Antitumor Activities of Anti-CD47 Antibodies Require Fc-FcγR interactions

doi: 10.1101/2023.06.29.547082

Figure Lengend Snippet: (A) Flow cytometry analysis of hCD47 and hSIRPα in red blood cells (RBC), platelets, CD3 + and CD11b + leucocytes isolated from peripheral blood of human (top) and hCD47/hSIRPα KI mice (bottom). (B) Average growth ± SEM of sq. MC38 hCD47 KI tumors in hCD47/hSIRPα KI mice, treated with chimeric anti-hCD47 ab Fc variants (chimeric-5F9) or isotype control (50 ug IT, d. 8,10,14 and 18). (C) Average of lung metastases ± SD of hCD47/hSIRPα KI mice inoculated IV with B16 hCD47 KI tumor cells, treated with chimeric anti-hCD47 ab Fc variants (chimeric-5F9) or isotype control (20 mg/Kg IP, d. 1,4,7 and 11). (D) Schematic drawing showing the two ab formats proposed for effective antitumor activity of anti-CD47 antibodies. Left: An ab blocking the interaction between CD47 and SIRPα AND an Fc domain engaging activating FcγRs. Right: A non-blocking anti-CD47 ab AND an Fc domain engaging activating FcγRs. (E) Average of lung metastases ± SD of hCD47/hSIRPα KI mice inoculated IV with B16 hCD47 KI tumor cells, treated with blocking (5F9-mIgG2a) and non-blocking (2D3-mIgG2a) chimeric anti-hCD47 antibodies or isotype control (20 mg/Kg IP, d. 1,4,7 and 11).

Article Snippet: The variable heavy and light regions of the anti-CD47 antibodies MIAP301 (anti-mCD47 ab) and 2D3 (nonblocking anti-hCD47 antibody) were decoded by mass spectrometry analysis (Bioinformatics Solutions, Inc.).

Techniques: Flow Cytometry, Isolation, Control, Activity Assay, Blocking Assay

Journal: Biomarker Research

Article Title: The landscape overview of CD47-based immunotherapy for hematological malignancies

doi: 10.1186/s40364-023-00456-x

Figure Lengend Snippet: Overall structures of CD47, SIRPα and CD47 complex. A Structure of the ectodomain of human CD47 (PDB#2VSC). B Interaction of CD47 with three major ligands (SIRPα, TSP-1 and integrin). The figure was created by Biorender.com. C Complete extracellular region of human SIRPα (PDB#2WNG). The structures were reconstructed using VMD software. Abbreviations: CD47, cluster of differentiation 47; IgSF, immunoglobulin superfamily; ITIM, immunoreceptor tyrosine-based inhibitory motif; SHPS-1/2, protein tyrosine phosphatase substrate-1/2; SIRPα, signal-regulatory protein α; TSP-1: thrombospondin-1

Article Snippet: GenSci-059 , GenSci-059 , GeneScience Pharmaceuticals Co Ltd , CD47 antagonist , anti-CD47 monoclonal antibody , Acute myeloid leukaemia , Phase I , / , NCT05263271 , /.

Techniques: Software

Journal: Biomarker Research

Article Title: The landscape overview of CD47-based immunotherapy for hematological malignancies

doi: 10.1186/s40364-023-00456-x

Figure Lengend Snippet: Macrophages distinguish between “self” or “non-self” by binding to SIRPα transmembrane protein on macrophage to form the CD47/SIRPα signaling complex. A CD47 expressed on cancer cell membrane binds to SIRPɑ on macrophage cell membrane to activate the “Don’t eat me” signal and block macrophage phagocytosis of cancer cells. B Blocking CD47-SIRPɑ interaction between cancer cell and macrophage induces phagocytosis by macrophage. Abbreviation: CD47, cluster of differentiation 47; SIRPα, signal-regulatory protein α

Article Snippet: GenSci-059 , GenSci-059 , GeneScience Pharmaceuticals Co Ltd , CD47 antagonist , anti-CD47 monoclonal antibody , Acute myeloid leukaemia , Phase I , / , NCT05263271 , /.

Techniques: Binding Assay, Membrane, Blocking Assay

Journal: Biomarker Research

Article Title: The landscape overview of CD47-based immunotherapy for hematological malignancies

doi: 10.1186/s40364-023-00456-x

Figure Lengend Snippet: Inhibiting CD47/SIRPα axis regulates the fate of cancer cells . Inhibiting the CD47/SIRPα axis can ( A ) directly enhance phagocytosis of macrophages to tumor cells; B transform tumor-associated macrophages into an antitumor state and increase the recruitment of macrophages in tumors; C promote phagocytosis by dendritic cells and antigen presentation to CD8 + T-cells; (D) destroy tumor cells by natural killer cell-mediated ADCC and CDC; E increase tumor cell death, inhibit tumor cell proliferation, and prevent tumor cell migration. Abbreviation: CD47, cluster of differentiation 47; SIRPα, signal-regulatory protein α; ACDD: antibody-dependent cellular cytotoxicity; CDC: complement-dependent cytotoxicity

Article Snippet: GenSci-059 , GenSci-059 , GeneScience Pharmaceuticals Co Ltd , CD47 antagonist , anti-CD47 monoclonal antibody , Acute myeloid leukaemia , Phase I , / , NCT05263271 , /.

Techniques: Immunopeptidomics, Migration

Journal: Biomarker Research

Article Title: The landscape overview of CD47-based immunotherapy for hematological malignancies

doi: 10.1186/s40364-023-00456-x

Figure Lengend Snippet: CD47 antagonists currently entering clinical trials for treatment of lymphomas

Article Snippet: GenSci-059 , GenSci-059 , GeneScience Pharmaceuticals Co Ltd , CD47 antagonist , anti-CD47 monoclonal antibody , Acute myeloid leukaemia , Phase I , / , NCT05263271 , /.

Techniques: Clinical Proteomics, Binding Assay

Journal: Biomarker Research

Article Title: The landscape overview of CD47-based immunotherapy for hematological malignancies

doi: 10.1186/s40364-023-00456-x

Figure Lengend Snippet: Published results of clinical trials on the use of CD47 antagonists in lymphomas

Article Snippet: GenSci-059 , GenSci-059 , GeneScience Pharmaceuticals Co Ltd , CD47 antagonist , anti-CD47 monoclonal antibody , Acute myeloid leukaemia , Phase I , / , NCT05263271 , /.

Techniques: Clinical Proteomics, Drug discovery

Journal: Biomarker Research

Article Title: The landscape overview of CD47-based immunotherapy for hematological malignancies

doi: 10.1186/s40364-023-00456-x

Figure Lengend Snippet: CD47 antagonists currently entering clinical trials for treatment of hematological tumors

Article Snippet: GenSci-059 , GenSci-059 , GeneScience Pharmaceuticals Co Ltd , CD47 antagonist , anti-CD47 monoclonal antibody , Acute myeloid leukaemia , Phase I , / , NCT05263271 , /.

Techniques: Clinical Proteomics, Binding Assay

Journal: Biomarker Research

Article Title: The landscape overview of CD47-based immunotherapy for hematological malignancies

doi: 10.1186/s40364-023-00456-x

Figure Lengend Snippet: Published results of clinical trials on the use of CD47 antagonists in hematological tumors

Article Snippet: GenSci-059 , GenSci-059 , GeneScience Pharmaceuticals Co Ltd , CD47 antagonist , anti-CD47 monoclonal antibody , Acute myeloid leukaemia , Phase I , / , NCT05263271 , /.

Techniques: Clinical Proteomics, Drug discovery

Journal: Biomarker Research

Article Title: The landscape overview of CD47-based immunotherapy for hematological malignancies

doi: 10.1186/s40364-023-00456-x

Figure Lengend Snippet: Future strategies for developing CD47 antagonists . Abbreviation: CD47, cluster of differentiation 47; SIRP, signal-regulatory protein

Article Snippet: GenSci-059 , GenSci-059 , GeneScience Pharmaceuticals Co Ltd , CD47 antagonist , anti-CD47 monoclonal antibody , Acute myeloid leukaemia , Phase I , / , NCT05263271 , /.

Techniques:

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Article Title: Anti-CD47 Monoclonal Antibody Therapy Reduces Ischemia-Reperfusion Injury of Renal Allografts in a Porcine Model of Donation after Cardiac Death

doi: 10.1111/ajt.14567

Figure Lengend Snippet: (A) The CD47mAb was strongly bound to the renal tissue immediately after flushing. (B) CD47mAb binding to glomeruli could be detected on day 5 after transplant. (These staining were performed on grafts from different animals.)

Article Snippet: Just prior to implantation, the grafts were flushed either with control (n=4) or a humanized CD47mAb (clone anti-CD47 649, Tioma Therapeutics, Inc, St. Louis, n=4) at a dosage of 10 mg per 250–300 g kidney.

Techniques: Binding Assay, Staining

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Article Title: Anti-CD47 Monoclonal Antibody Therapy Reduces Ischemia-Reperfusion Injury of Renal Allografts in a Porcine Model of Donation after Cardiac Death

doi: 10.1111/ajt.14567

Figure Lengend Snippet: Graft blood flow prior (0s) and post reperfusions at 1s, 15s, 30s, and 60s were studied using an in vivo imaging system (n=2/group). (A) Representative perfusion using ICG fluorescence imaging are shown at time points 0, 16 and 60 seconds after release of clamps (see Figure S1 for additional images). (B) The fluorescence density values of the region of interest (ROI) were extracted to evaluate reperfusion characteristics of the grafts. CD47mAb-treated grafts had more uniform and greater average tissue perfusion as compared to control organs. (C) The repeated measure two-way ANOVA shows that Time (p<0.001), Treatment (p=0.002), and Interaction (p<0.001) terms are all significant, indicating florescent density differed by treatment and over time.

Article Snippet: Just prior to implantation, the grafts were flushed either with control (n=4) or a humanized CD47mAb (clone anti-CD47 649, Tioma Therapeutics, Inc, St. Louis, n=4) at a dosage of 10 mg per 250–300 g kidney.

Techniques: In Vivo Imaging, Fluorescence, Imaging, Control

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Article Title: Anti-CD47 Monoclonal Antibody Therapy Reduces Ischemia-Reperfusion Injury of Renal Allografts in a Porcine Model of Donation after Cardiac Death

doi: 10.1111/ajt.14567

Figure Lengend Snippet: (A) Serum creatinine, blood urea nitrogen (BUN), and phosphorus were significantly decreased, while the calcium levels were significantly increased in the CD47mAb-treated group than that in the control group. (B) Histological study of pig kidney grafts at day 5 post-KTx indicated that CD47mAb treated grafts had significantly less evidence of acute tubular injury (ATI) compared with the control group. (C) Animals with CD47mAb treated grafts had significantly earlier urination than that in control (n=4/group, CD47mAb treatment versus control, *p<0.05 or **p<0.01, respectively).

Article Snippet: Just prior to implantation, the grafts were flushed either with control (n=4) or a humanized CD47mAb (clone anti-CD47 649, Tioma Therapeutics, Inc, St. Louis, n=4) at a dosage of 10 mg per 250–300 g kidney.

Techniques: Control

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Article Title: Anti-CD47 Monoclonal Antibody Therapy Reduces Ischemia-Reperfusion Injury of Renal Allografts in a Porcine Model of Donation after Cardiac Death

doi: 10.1111/ajt.14567

Figure Lengend Snippet: (A) Revealed by qRT-PCR, CD47mAb-treated organs showed significantly less expression in each of these oxidative injury-related genes of superoxide dismutase-1 (sod-1), glutathione peroxidase-1 (gpx-1), thioredoxin (txn), except heme oxygenase-1 (hmox-1) compared to control. (B) Immunofluorescence staining revealed a decreased expression of Voltage-dependent anion-selective channel protein 1 (VDAC-1) and poly (ADP-ribose) polymerase (PARP) in the CD47mAb-treated tissues than in control. (C) Western blotting and (D) densitometry analysis also support that the protein levels of VDAC-1 and PARP are decreased in the grafts treated with CD47mAb compared with control (n=4/group, *p<0.05, ** p<0.01, or *** p<0.001, respectively).

Article Snippet: Just prior to implantation, the grafts were flushed either with control (n=4) or a humanized CD47mAb (clone anti-CD47 649, Tioma Therapeutics, Inc, St. Louis, n=4) at a dosage of 10 mg per 250–300 g kidney.

Techniques: Quantitative RT-PCR, Expressing, Control, Immunofluorescence, Staining, Western Blot

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Article Title: Anti-CD47 Monoclonal Antibody Therapy Reduces Ischemia-Reperfusion Injury of Renal Allografts in a Porcine Model of Donation after Cardiac Death

doi: 10.1111/ajt.14567

Figure Lengend Snippet: (A) qRT-PCR showed the relative mRNA levels of il-2, il-6, tgf-b, and inf-g were significantly lower in the CD47mAb treated renal allografts than that in control at day 5 after kidney transplantation. (B) Immunofluorescence staining indicated the CD4+ and CD8+ cells infiltration were significantly decreased in the CD47mAb treated renal allografts than that in the control (n=4/group, *p<0.05 or ** p<0.01, respectively).

Article Snippet: Just prior to implantation, the grafts were flushed either with control (n=4) or a humanized CD47mAb (clone anti-CD47 649, Tioma Therapeutics, Inc, St. Louis, n=4) at a dosage of 10 mg per 250–300 g kidney.

Techniques: Quantitative RT-PCR, Control, Transplantation Assay, Immunofluorescence, Staining

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Article Title: Anti-CD47 Monoclonal Antibody Therapy Reduces Ischemia-Reperfusion Injury of Renal Allografts in a Porcine Model of Donation after Cardiac Death

doi: 10.1111/ajt.14567

Figure Lengend Snippet: (A) Immunofluorescence staining showed a reduction of matrix metalloproteinase-2 (MMP-2) and MMP-9 in CD47mAb treated renal allografts than that in control. Western blotting (B) and densitometry analysis (C) confirmed the decreasing expression of MMP-2 and MMP-9 in renal grafts treated with CD47mAb compared to control (n=4/group, *p<0.05 or ** p<0.01, respectively).

Article Snippet: Just prior to implantation, the grafts were flushed either with control (n=4) or a humanized CD47mAb (clone anti-CD47 649, Tioma Therapeutics, Inc, St. Louis, n=4) at a dosage of 10 mg per 250–300 g kidney.

Techniques: Immunofluorescence, Staining, Control, Western Blot, Expressing

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Article Title: Anti-CD47 Monoclonal Antibody Therapy Reduces Ischemia-Reperfusion Injury of Renal Allografts in a Porcine Model of Donation after Cardiac Death

doi: 10.1111/ajt.14567

Figure Lengend Snippet: (A) Immunofluorescence staining showed a decrease of Bcl-2-associated X protein (BAX) and Caspase-3 in the CD47mAb treated renal allografts compared to control. Western blotting (B) and densitometry analysis (C) confirmed the decreasing expression of BAX and Caspase-3 in renal grafts treated with CD47mAb than that in control (n=4/group, *p<0.05 or ** p<0.01, respectively).

Article Snippet: Just prior to implantation, the grafts were flushed either with control (n=4) or a humanized CD47mAb (clone anti-CD47 649, Tioma Therapeutics, Inc, St. Louis, n=4) at a dosage of 10 mg per 250–300 g kidney.

Techniques: Immunofluorescence, Staining, Control, Western Blot, Expressing